Clinical Trials in Lecco, Italy
17 recruiting
Showing 1–20 of 21 trials
Recruiting
Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled285 locationsNCT07207811
Recruiting
Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
Incyte Corporation466 enrolled133 locationsNCT07214779
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled288 locationsNCT06868277
Recruiting
Phase 3
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
AstraZeneca800 enrolled201 locationsNCT06079671
Recruiting
Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AbbVie520 enrolled264 locationsNCT05445778
Recruiting
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
Adjuvant TherapyCDK4/6 Inhibitor
European Institute of Oncology750 enrolled18 locationsNCT07180693
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Phase 2
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
North Eastern German Society of Gynaecological Oncology640 enrolled47 locationsNCT05460000
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Epithelial Ovarian Cancer
AstraZeneca1,100 enrolled125 locationsNCT07218809
Recruiting
Not Applicable
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
GlioblastomaIDH Wild-type and STAT3-positive Glioblastoma
Istituto Oncologico Veneto IRCCS110 enrolled16 locationsNCT06964815
Recruiting
Phase 3
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Ovarian Cancer
ARCAGY/ GINECO GROUP250 enrolled72 locationsNCT06476184
Recruiting
Prevention ICONA Dedicated Ensemble
HIV-1-infectionHIVPrEP+3 more
Fondazione ICONA5,000 enrolled53 locationsNCT07186244
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
Phase 3
MYTHS - MYocarditis THerapy With Steroids
Myocarditis Acute
Niguarda Hospital288 enrolled49 locationsNCT05150704
Recruiting
Not Applicable
TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial
Multiple SclerosisParkinson DiseaseNeurologic Diseases, General
Fondazione Don Carlo Gnocchi Onlus300 enrolled6 locationsNCT06685744
Recruiting
Neurosurgical Outcome Network
DepressionTrigeminal NeuralgiaObsessive-Compulsive Disorder+20 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta4,500 enrolled27 locationsNCT06724029
Recruiting
Phase 4
Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer
Endometrial Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano84 enrolled8 locationsNCT06726291
Recruiting
Phase 2Phase 3
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Kartos Therapeutics, Inc.268 enrolled83 locationsNCT05797831